The Greenshell™ mussel (GSM), Perna canaliculus, industry in New Zealand (NZ) is the largest aquaculture sector in the country. In 2006, the export earnings were valued at US$145 million which represented 65% of NZ aquaculture earnings. Historically, and at present, GSM production involves the capture of wild mussels on ropes followed by on-growing of these animals to market size (approximately 14 months). However, hatchery production of GSM has been developed in recent years. Hatchery production will alleviate the seasonal uncertainties of current techniques and allow the benefits of selective breeding programs. To date, efforts to produce commercial quantities of GSM in hatcheries have been hampered by unreliable larval rearing. These problems were often alleviated by antibiotic use, which implied bacterial pathogens as the cause. Yet, the ongoing use of antibiotics is not sustainable because of increasing legislative restrictions on their use and the possible emergence of antibiotic resistant bacteria. Hence, the identification and use of novel probiotics was investigated as an alternative. Because of a lack of previous work, it was necessary to investigate the bacterial pathogenesis of GSM larvae in the initial stages and, hence, to determine the cause of disease against which the probiotics would be active. Twenty-two bacterial strains, isolated from compromised larvae, were screened for larval toxicity using a larval bioassay. Two strains were identified as potential pathogens. Sequencing of the 16S rRNA gene identified Vibrio splendidus and Vibrio sp. DO1, a Vibrio coralliilyticus/neptunius-like isolate, as pathogens of GSM larvae. These strains had the- ability to cause 83 and 75% GSM larval mortality in vitro respectively, at a concentration 102 CFU ml-1. Histopathology indicated the route of infection was via the digestive system. Using healthy larvae as target hosts, Koch's postulates were confirmed for the two isolates. Although two bacterial pathogens were identified, the successful design and implementation of protective measures in the hatchery still required an understanding of the dynamics of the infection process. Developing an in situ experimental model for infection was therefore paramount. The minimum effective pathogenic dose (MEPD) of V. splendidus (105 CFU ml-1) and Vibrio sp. DO1 (106 CFU ml-1) was demonstrated for GSM larvae during hatchery production. In a flow-through water hatchery system, larvae given 1-2 hours of static water exposure with these pathogen doses, after which flowthrough processes resumed, averaged 58% and 69% cumulative mortality, respectively, on the fourth day following pathogen exposure. Larvae exposed to a dosage one order of magnitude greater than the MEPD, had higher mortalities of 73% and 96% for V. splendidus and Vibrio sp. DO1 respectively. These four levels of mortality were significantly greater than those of the non-exposed control larvae, averaging 23% in the experiments involving V. splendidus and 35% with Vibrio sp. DO1. Experiments were repeated four times to establish reproducibility. The infection models were reproducible and provided a tool to assess measures for the protection of GSM larvae against infection in the hatchery environment. A bioassay was developed to screen and select bacterial strains as potential probiotics for GSM larvae. Sixty-nine isolates originating from a GSM hatchery environment were tested for probiotic activity in larval pathogen-challenge bioassays conducted in tissue culture dishes (TCDs). Vibrio sp. DO1 and V. splendidus were the tested pathogens. Forty of the tested isolates afforded larval survival significantly greater than pathogen controls (p < 0.05). The bioassay technique achieved a 58% success rate in searching for putative probiotics and highlighted the benefit of including the host animal in the first stage of the screening procedure. The time of inoculation of putative probiotic strains prior to pathogen challenge influenced the outcome of the assay. A pre-exposure period of 20 hours revealed a greater number of potential probiotics than a two-hour pre-exposure period. Pilot challenge tests, under normal hatchery conditions, confirmed the usefulness of the TCD screening method in recognising effective probiotics. Following hatchery pilot trials, two probiotic strains were chosen for further study, namely strains 0444 and 0536. Sequencing of the 16S rRNA gene and phylogenetic analysis identified the strains as Alteromonas macleodii 0444 and Neptunomonas sp. 0536. Both probiotics were evaluated separately in a GSM hatchery facility during routine larval rearing and when the larvae were challenged with a high and low pathogenic dose of Vibrio sp. DO1 and V. splendidus. In all experiments, probiotic application significantly improved larval survival, if administered prior to pathogen exposure. Across all experiments, larvae that were exposed to the high and low dosages of pathogens averaged 14% and 36% survival respectively on the fourth day following pathogen exposure. If the probiotics were administered prior to pathogen challenge, larval survival averaged 50% and 66% respectively. Non-inoculated control larvae and larvae administered the probiotic alone demonstrated 67% and 79% survival respectively. In a repeat experiment, these benefits were reproduced, with the exception of A. macleodii 0444 trialled against V. splendidus. Neptunomonas sp. 0536 appeared to suppress naturally occurring vibrios in the culture environment of healthy GSM larvae. This was the first time A. macleodii and Neptunomonas sp. were demonstrated as probiotic bacteria. Many studies document probiotic application in aquaculture under conditions of pathogen attack, yet few describe the use of probiotics during routine production. The effects of administering the probiotic, A. macleodii 0444, during routine GSM larvae production, were compared against larvae from the same cohort that were not treated with the probiotic. The probiotic was administered daily for the first 11 days of the larval period and was provided at two concentrations, 107 CFU ml-1 and 108 CFU ml-1. Measures of larval swimming activity, gut colouration, lipid levels, larval survival, larval size and settlement success were recorded. There were minimal differences in all parameters between larvae provided the probiotic and control larvae. Probiotic treated larvae consumed more food and had higher lipid levels at the end of the larval period, but these were not statistically significant. All treatments completed the larval phase and settled successfully after metamorphosis. Survival at the end of the larval period was 37.2%, 38.8%, and 34.8% for control, 107 CFU ml-1 and 108 CFU ml-1 treatments respectively. The probiotic was still detected in larvae seven days after the final addition to the tanks. Animals were further grown in the field at a commercial farm. The probiotic was not detected in mussels at four months after leaving the hatchery. Combination use of the two probiotics, A. macleodii 0444 and Neptunomonas sp. 0536, was investigated to determine whether additive protection against pathogen attack with Vibrio sp. DO1 and V. splendidus was afforded to GSM larvae. The effects of combination administration were compared with larvae administered each probiotic as single strains and non-inoculated larvae. Additionally, two concentrations were tested for each probiotic, both singly and in combination, 107 and 108 CFU ml-1. Larvae were administered probiotics daily for the first six days, challenged with pathogens on the third day and then reared until settlement (day 19). Although protection against pathogen attack was observed in combination treatments, when compared with single-strain administration, additive protection was not apparent. Administration of 108 CFU ml-1 levels of probiotics, both singly and in combination, afforded larval survival slightly better than 107 CFU ml-1 levels, although this was rarely statistically significant. On the other hand, the higher levels of probiotic led to smaller larvae and lower feed rates for the majority of the 19-day trial. At the end of the study, larval sizes were smaller in the treatment applied a combination of probiotics at 108 CFU ml-1 than those of the other treatments. Additionally, towards the end of the larval period, feed consumption in the combination 108 CFU ml-1 treatment was similar to that witnessed in the other probiotic treatments one day previously. This suggested that either the larvae were compromised or they were growing slower. Despite a lack of additive protection against a single strain pathogen attack being demonstrated, the potential benefit of multi-strain probiotics, as prophylactic measures against every-day microbial encounters in larviculture, would remain. Although 108 CFU ml-1 levels appeared to protect against pathogen attack slightly better, they were also potentially detrimental to normal larval rearing when administered in combination. Following the successful completion of the larval period and pathogen protection afforded with a combination of probiotics at 107 CFU ml-1, this level was recommended as the best concentration of each probiotic where combination administration would be applied. The work presented in this thesis supports the use of A. macleodii 0444 and Neptunomonas sp. 0536 in the routine rearing of GSM larvae. The ability to produce settled juvenile mussels, equal in numbers to those produced in normal healthy conditions, plus the benefits against pathogen attack led to the recommendation of their use on a routine prophylactic basis in GSM larval rearing. Their use for this purpose is intended in the near future. A provisional patent has been prepared and will be submitted shortly. It is anticipated that future work will continue with these probiotic strains to determine their potential benefit for other aquaculture species.
| Identifer | oai:union.ndltd.org:ADTP/282759 |
| Date | January 2009 |
| Creators | Kesarcodi-Watson, Aditya |
| Source Sets | Australiasian Digital Theses Program |
| Language | English |
| Detected Language | English |
Page generated in 0.0113 seconds